
Gastrointestinal Cancer
Latest News
Latest Videos

CME Content
More News






The combination regimen of the PD-1 inhibitor nivolumab (Opdivo) plus nab-paclitaxel and gemcitabine was found to demonstrate encouraging clinical activity and low toxicity levels in patients with metastatic pancreatic cancer.
















Masanori Terashima, MD, PhD, FACS, Shizuoka Cancer Center, chairman of the Japanese Clinical Oncology Group, discusses the future of bursectomy and omentectomy for patients with gastric cancer.

The combination of nanoparticle albumin-bound-paclitaxel and gemcitabine led to no new or unexpected adverse events in a small study of patients with locally advanced pancreatic cancer.

Jonathan Strosberg, MD, discusses the latest results from the NETTER-1 trial in midgut neuroendocrine tumors.















































